Author

Rudy J. Richardson

University of MichiganPrimary ORCID profile (0000-0002-2028-5723 · 1 paper)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Rudy J. RichardsoniD1 paper · University of Michigan

Biology Disciplines

Click to filter author papers

Systems Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Organism:E. coli· 1 Approach:machine learning (classical)· 1 Assay:metabolomics· 1 Assay:proteomics· 1

Frequent Co-Authors

Aaron M. RobidaiD· 1 shared David H. ShermaniD· 1 shared Debmalya Sarkar· 1 shared Harkirat Singh AroraiD· 1 shared Jon Albo· 1 shared Katherine L. LeviD· 1 shared Madeline R. ShayiD· 1 shared Margaret M. ReuteriD· 1 shared

Activity by Year

2024-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperSystems Biology

Aaron M. RobidaORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Ultra-high-throughput screening of antimicrobial combination therapies using a two-stage transparent machine learning model

Margaret M. Reuter, Katherine L. Lev, Jon Albo, Harkirat Singh Arora, Nemo Liu, Shenghao Tan, Madeline R. Shay, Debmalya Sarkar, Aaron M. Robida, David H. Sherman, Rudy J. Richardson, Nate Cira, Sriram Chandrasekaran

This paper introduces M2D2, a two-stage ML model that identifies synergistic antimicrobial drug combinations and validates them experimentally against E. coli.

bioRxiv · Nov 25, 2024 · PreprintSystems Biology